ES2714576T3 - Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos - Google Patents

Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos Download PDF

Info

Publication number
ES2714576T3
ES2714576T3 ES15814466T ES15814466T ES2714576T3 ES 2714576 T3 ES2714576 T3 ES 2714576T3 ES 15814466 T ES15814466 T ES 15814466T ES 15814466 T ES15814466 T ES 15814466T ES 2714576 T3 ES2714576 T3 ES 2714576T3
Authority
ES
Spain
Prior art keywords
mmol
amino
methoxy
phenyl
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15814466T
Other languages
English (en)
Spanish (es)
Inventor
Zhaozhong Ding
Minghui Zhang
Shuhui Chen
Xile Liu
Yidong Zhu
Chuanwen Fan
Baoping Zhao
Long Zhang
Yingying Yang
Qingmei Zheng
Shansong Zheng
Haiwen Wan
Jinqing Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Pharmaceutical Co Ltd
Original Assignee
Qilu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410317076.7A external-priority patent/CN105330698B/zh
Application filed by Qilu Pharmaceutical Co Ltd filed Critical Qilu Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2714576T3 publication Critical patent/ES2714576T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ES15814466T 2014-07-04 2015-06-29 Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos Active ES2714576T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410317076.7A CN105330698B (zh) 2014-07-04 2014-07-04 螺环芳基磷氧化物和硫化物
CN201510350019 2015-06-23
PCT/CN2015/082605 WO2016000581A1 (zh) 2014-07-04 2015-06-29 螺环芳基磷氧化物和芳基磷硫化物

Publications (1)

Publication Number Publication Date
ES2714576T3 true ES2714576T3 (es) 2019-05-29

Family

ID=55018447

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15814466T Active ES2714576T3 (es) 2014-07-04 2015-06-29 Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos

Country Status (7)

Country Link
US (1) US10053477B2 (OSRAM)
EP (1) EP3165530B1 (OSRAM)
JP (1) JP6487527B2 (OSRAM)
ES (1) ES2714576T3 (OSRAM)
PL (1) PL3165530T3 (OSRAM)
TW (1) TWI571471B (OSRAM)
WO (1) WO2016000581A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6487527B2 (ja) 2014-07-04 2019-03-20 チル ファーマシューティカル カンパニー リミテッド スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
JP7166331B2 (ja) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
US20210009613A1 (en) * 2017-12-12 2021-01-14 Shenzhen Targetrx, Inc. Arylphosphine oxides for inhibiting kinase activity
EP3715343B1 (en) * 2017-12-21 2024-02-14 Shenzhen TargetRx, Inc. Diphenylaminopyrimidine compound for inhibiting kinase activity
WO2019201334A1 (zh) * 2018-04-20 2019-10-24 南京明德新药研发有限公司 二甲基氧膦类化合物
CN113302196B (zh) * 2019-01-17 2023-08-04 贝达药业股份有限公司 Egfr抑制剂及其组合物和应用
AU2020404305A1 (en) * 2019-12-19 2022-08-04 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
WO2023280090A1 (zh) * 2021-07-05 2023-01-12 齐鲁制药有限公司 一种药用组合物及其制备方法和用途
WO2023078411A1 (zh) * 2021-11-05 2023-05-11 南京明德新药研发有限公司 氮杂螺环化合物
CN118338913A (zh) * 2022-01-18 2024-07-12 齐鲁制药有限公司 螺环芳基磷氧化物与抗vegf抗体的药物组合
TW202339767A (zh) * 2022-01-18 2023-10-16 大陸商齊魯製藥有限公司 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途
CN118891264A (zh) * 2022-08-01 2024-11-01 齐鲁制药有限公司 螺环胺类芳基磷氧化合物的晶型及其制备方法
WO2025202955A1 (en) 2024-03-28 2025-10-02 Pi Industries Ltd. Fused bicyclic compounds and their use as pest control agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) * 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2011053476A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
JP2013539795A (ja) 2010-10-14 2013-10-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖の阻害方法
FR2974088A1 (fr) 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
CN102731413A (zh) 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
WO2013138210A1 (en) 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
AU2013239663A1 (en) 2012-03-28 2014-10-09 Synta Pharmaceuticals Corp. Triazole derivatives as HSP90 inhibitors
JP6469567B2 (ja) * 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2013177092A1 (en) 2012-05-23 2013-11-28 Sunshine Lake Pharma Co., Ltd. Substituted alkynyl pyridine compounds and methods of use
WO2013192512A1 (en) 2012-06-22 2013-12-27 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2014002922A1 (ja) 2012-06-26 2014-01-03 アステラス製薬株式会社 抗癌剤の併用による癌治療方法
WO2014006554A1 (en) 2012-07-03 2014-01-09 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US9446039B2 (en) 2012-08-27 2016-09-20 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Aminoheteroaryl compounds as MTH1 inhibitors
JP6487527B2 (ja) 2014-07-04 2019-03-20 チル ファーマシューティカル カンパニー リミテッド スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）

Also Published As

Publication number Publication date
WO2016000581A1 (zh) 2016-01-07
JP2017521436A (ja) 2017-08-03
TWI571471B (zh) 2017-02-21
EP3165530A4 (en) 2017-07-26
US20170129909A1 (en) 2017-05-11
TW201604202A (zh) 2016-02-01
US10053477B2 (en) 2018-08-21
EP3165530B1 (en) 2018-12-05
EP3165530A1 (en) 2017-05-10
JP6487527B2 (ja) 2019-03-20
PL3165530T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
ES2714576T3 (es) Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos
CN105330698B (zh) 螺环芳基磷氧化物和硫化物
JP6577613B2 (ja) キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
ES2670416T3 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer
CA2952992C (en) Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
IL267158A (en) Amino-triazopyridine compounds and their use in cancer treatment
TW202417455A (zh) 新穎三雜環化合物及藥學組成物
KR20250070059A (ko) 신규한 테트라헤테로사이클 화합물
EP3837250A1 (en) Pyrazine compounds and uses thereof
JP2025540756A (ja) トリアゾール化合物、その製造方法と医薬的用途
ES2787449T3 (es) Compuesto de alfa y beta-amida insaturada derivado de benzotriazol usado como inhibidor de TGF-betaRI
BR112017019286B1 (pt) Derivados de 2h-pirazol substituídos ou um sal farmacêuticamente aceitável dos mesmos
AU2016254385A1 (en) JAK inhibitors
AU2015276699B2 (en) Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor
CN114206883A (zh) 氧代吡啶稠环衍生物及包含该衍生物的药物组合物
WO2018103688A1 (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS
CN111471059A (zh) Pde9抑制剂及其用途
AU2022202886A1 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
CN121013849A (zh) 作为wrn抑制剂的杂环化合物
ES2776359T3 (es) Quinazolin-thf-aminas halogenadas como inhibidores de PDE1
CA3231988A1 (en) Azaindazole macrocycle compound and use thereof
ES2907574T3 (es) Proceso para la preparación de compuestos inhibidores de pi3k triciclicos y métodos para su utilización para el tratamiento del cáncer.
CN116322699B (zh) 一类并环化合物及其制备和应用
ES2896938T3 (es) Inhibidores de GSK-3
TWI685494B (zh) 稠環或三環芳基嘧啶化合物用作激酶抑制劑